Rolando Toyos
Toyos Clinic, USA
Title: Title: Lifitegrast and Other New Topical Medications for Dry Eye Disease
Biography
Biography: Rolando Toyos
Abstract
Over the last few years, more companies are spending more research dollars in developing new medications for dry eye disease (DED). We have completed and have several on going studies on different drops specifically designed for DED. Recently a medication, lifitegrast was approved. Lifitegrast is an anti-inflammatory drop that inhibits the binding of LFA-1 to ICAM-1 down-regulating the inflammation mediated by T lymphocytes. It is the only medication FDA approved for the signs and symptoms of DED. We will present FDA and our current research of this novel drop. We will also cover our work with platelet rich plasma eye drops, optimel, and oculocin. All work will include OSDI data, TBUT, and effects on lid margin disease.